Today: 29 January 2026
Subscribe
Browse Category

NASDAQ:ARQT News 30 December 2025 - 12 January 2026

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

New York, January 12, 2026, 15:41 ET — Regular session Shares of Arcutis Biotherapeutics dropped 8.7% on Monday, slipping $2.46 to $25.76, following the company’s update on its 2026 priorities. The dermatology drugmaker set a $455 million to $470 million target for net product sales in its ZORYVE franchise. The stock hit a session low of $25.51 during trading. The…
12 January 2026
·····
Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

New York, Jan 9, 2026, 15:46 EST — Regular session Arcutis Biotherapeutics shares slid 5.3% to $28.29 in afternoon trading on Friday, after climbing as high as $30.70 earlier. The stock was last at the session low. The move followed a cooler U.S. payrolls report, which reinforced expectations the Federal Reserve will keep rates steady in coming weeks. High-growth biotech…
9 January 2026
·····
Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates

Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates

NEW YORK, January 1, 2026, 21:21 ET — Market closed With U.S. markets closed for New Year’s Day, shares of Arcutis Biotherapeutics Inc (ARQT) last closed up 3.42% at $29.04 in the final trading session of 2025. The stock ranged from $28.08 to $29.67 on volume of about 1.87 million shares. ARQT is up about 99% over the past year…
2 January 2026
····
Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day

Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day

NEW YORK, January 1, 2026, 07:57 ET — Market closed. Arcutis Biotherapeutics shares are in focus after a regulatory filing showed an executive planned to sell a small block of stock, with U.S. markets closed on Thursday for New Year’s Day. The dermatology drugmaker last closed up 3.4% at $29.04 on Dec. 31. Intercontinental Exchange The disclosure matters because investors…
1 January 2026
····
Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade

Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade

NEW YORK, December 31, 2025, 10:33 ET — Regular session Shares of Arcutis Biotherapeutics Inc rose 3.8% to $29.16 by 10:33 a.m. ET on Wednesday, extending gains in the final U.S. trading session of 2025. The Nasdaq-listed dermatology drugmaker traded between $28.08 and $29.19, with about 181,000 shares changing hands. The move puts ARQT within striking distance of $30 and…
31 December 2025
·····
Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

NEW YORK, December 30, 2025, 14:45 ET — Regular session Arcutis Biotherapeutics shares fell 2.9% to $27.74 in afternoon trading on Tuesday, after moving between $27.72 and $28.65. Volume was about 0.6 million shares. The drop outpaced broader biotech gauges, with the SPDR S&P Biotech ETF down about 1.5% and the iShares Nasdaq Biotechnology ETF off about 1.1%. That matters…
30 December 2025
·····

Stock Market Today

  • Heritage Insurance Holdings Shows Strong EPS Growth and Insider Confidence
    January 29, 2026, 7:38 AM EST. Heritage Insurance Holdings (NYSE:HRTG) reported a remarkable 110% year-on-year earnings per share (EPS) growth, rising from $2.43 to $5.11 over the past 12 months. This growth is complemented by improving revenue and earnings before interest and tax (EBIT) margins, which increased by 12.4 percentage points to 25%, signaling robust business performance. Insiders hold a significant 24% stake valued at $175 million, aligning their interests with shareholders. While past data shows rapid EPS gains, investors are advised to prioritize recent growth trends over longer-term estimates. The combination of strong fundamentals and insider confidence positions HRTG as an appealing option for those prioritizing profitability and sustainable growth in their portfolio.
Go toTop